Differences

This shows you the differences between two versions of the page.

--- helen_groves [2022/05/09 09:46]
liam [Remdesivir]
+++ helen_groves [2022/05/09 10:00] (current)
liam
@@ Line 21: / Line 21: @@
 ==== Remdesivir ====
-Groves was an author on a study on [[remdesivir]], funded by [[pharmaceutical_companies:Gilead Sciences]] and the [[National Institutes of Health]] (NIH), paid to the institutions of her colleagues.((Chiotos, K., Hayes, M., Kimberlin, D. W., Jones, S. B., James, S. H., Pinninti, S. G., Yarbrough, A., Abzug, M. J., MacBrayne, C. E., Soma, V. L., Dulek, D. E., Vora, S. B., Waghmare, A., Wolf, J., Olivero, R., Grapentine, S., Wattier, R. L., Bio, L., Cross, S. J., & Dillman, N. O. (2020). //Multicenter interim guidance on use of antivirals for children with COVID-19/SARS-CoV-2.// Journal of the Pediatric Infectious Diseases Society. https://doi.org/10.1093/jpids/piaa115)) The study was also facilitated by the [[Sharing Antimicrobial Reports for Pediatric Stewardship]] (SHARPS) Collaborative, which is sponsored by [[medical_technology_companies:BioFire Diagnostics]] (a [[pharmaceutical_companies:BioMérieux]] company) [[pharmaceutical_companies:Evivo]], [[pharmaceutical_companies:GlaxoSmithKline]], [[pharmaceutical_companies:Horizon Pharma]], [[pharmaceutical_companies:Roche]].(())
+Groves was an author on a study on [[remdesivir]], funded by [[pharmaceutical_companies:Gilead Sciences]] and the [[National Institutes of Health]] (NIH), paid to the institutions of her colleagues.((Chiotos, K., Hayes, M., Kimberlin, D. W., Jones, S. B., James, S. H., Pinninti, S. G., Yarbrough, A., Abzug, M. J., MacBrayne, C. E., Soma, V. L., Dulek, D. E., Vora, S. B., Waghmare, A., Wolf, J., Olivero, R., Grapentine, S., Wattier, R. L., Bio, L., Cross, S. J., & Dillman, N. O. (2020). //Multicenter interim guidance on use of antivirals for children with COVID-19/SARS-CoV-2.// Journal of the Pediatric Infectious Diseases Society. https://doi.org/10.1093/jpids/piaa115)) It was funded by the [[Agency for Healthcare Research and Quality]].
+The study was also facilitated by the [[Sharing Antimicrobial Reports for Pediatric Stewardship]] (SHARPS) Collaborative, which is sponsored by [[medical_technology_companies:BioFire Diagnostics]] (a [[pharmaceutical_companies:BioMérieux]] company), [[medical_technology_companies:Cepheid]], [[pharmaceutical_companies:Evivo]], [[pharmaceutical_companies:GlaxoSmithKline]], [[pharmaceutical_companies:Horizon Pharma]], [[medical_technology_companies:Magnolia Medical Technologies]], [[pharmaceutical_companies:Roche]] and [[medical_technology_companies:VigiLanz]].((//Conference Sponsors.// SHARPS. Retrieved May 9, 2022, from https://web.archive.org/web/20220509075141/http://pediatrics.wustl.edu/sharps/Annual-Conference/Sponsors))
+==== Influenza ====
+Groves published research on the impact of [[COVID-19]] on [[influenza]].((Groves, H. E., Piché-Renaud, P.-P., Peci, A., Farrar, D. S., Buckrell, S., Bancej, C., Sevenhuysen, C., Campigotto, A., Gubbay, J. B., & Morris, S. K. (2021). //The impact of the COVID-19 pandemic on influenza, respiratory syncytial virus, and other seasonal respiratory virus circulation in Canada: A population-based study.// The Lancet Regional Health - Americas, 1, 100015. https://doi.org/10.1016/j.lana.2021.100015))
 ===== Relationship with pharmaceutical companies =====
 Groves received honoraria from [[pharmaceutical_companies:AbbVie]].((Groves, H. E., Papenburg, J., Mehta, K., Bettinger, J. A., Sadarangani, M., Halperin, S., & Morris, S. (2021). //1188. The Effect Of The COVID-19 Pandemic On Influenza-Related Hospitalization, Intensive Care Admission And Mortality In Canadian Children.// Open Forum Infectious Diseases, 8(Supplement_1), S685–S686. https://doi.org/10.1093/ofid/ofab466.1380))